Repurposing of Maraviroc for the treatment of neuropathic pain

重新利用马拉韦罗治疗神经性疼痛

• 批准号: 10586296
• 负责人: Jun Wang
• 金额: --
• 依托单位: JAMES J PETERS VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-12-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10586296
• 关键词: Adenylate Cyclase; Adrenal Cortex Hormones; Adult; Adverse effects; Affect; Amygdaloid structure; Animal Model; Anterior; Antiepileptic Agents; Anxiety; Blood; Brain; CCR5 gene; Cannabinoids; Cells; Cellular Structures; Centers for Disease Control and Prevention (U.S.); Chemotactic Factors; Clinical; Data; Development; Economics; Emotional; FDA approved; Female; Fiber; Filament; Flow Cytometry; Future; Gene Chips; Gene Expression; General Population; Health; Health care facility; Healthcare Systems; Human; Immune; Immunologics; Inflammation; Injections; Injury; Intervention; Lesion; Ligands; MAP Kinase Gene; Mechanics; Mental Depression; Mental disorders; Metabolism; Molecular; Mus; Natural Killer Cells; Nerve; Nerve Degeneration; Nervous system structure; Neuraxis; Neuroglia; Neuronal Plasticity; Neurons; Neuropathy; Non-Steroidal Anti-Inflammatory Agents; Operative Surgical Procedures; Opiate Addiction; Opioid; Outcome; Outcome Study; PI3K/AKT; Pain; Pain intensity; Pain management; Patients; Peripheral; Peripheral Nerves; Peripheral Nervous System; Peripheral nerve injury; Pharmaceutical Preparations; Pharmacology; Pharmacotherapy; Phenotype; Plasma; Play; Prevalence; Primary Health Care; Quality of life; RANTES; Randomized; Reporting; Role; Safety; Sampling; Signal Transduction; Spinal Ganglia; Steroids; T-Lymphocyte; Techniques; Testing; Therapeutic; Tissues; Tricyclic Antidepressive Agents; Trigeminal Neuralgia; Tumor Cell Invasion; Up-Regulation; Veterans; Weight-Bearing state; Well in self; antagonist; atypical facial pain; base; cancer pain; cell type; chemokine; chemokine receptor; chemotherapy; chronic pain; clinically significant; comorbidity; cytokine; discogenic pain; follow-up; macrophage; male; migration; monocyte; mouse model; nano-string; nerve injury; neural stimulation; neurobehavioral test; neuroinflammation; neuropathology; neurotransmission; novel; novel therapeutic intervention; pain reduction; pain relief; pain sensitivity; painful neuropathy; pre-clinical; receptor; response; sciatic nerve; sham surgery; side effect; social; spared nerve; spontaneous pain; suicidal; synaptic function; translational study; treatment group

SUMMARY/ABSTRACT Chronic pain is one of the most common health problems in adult and has profound impact on physical as well as mental wellbeing. According to CDC data brief in 2020, 20.4% of adults in the U.S. have chronic pain. The prevalence is even higher in veterans. Among Veterans receiving primary care in VA healthcare facilities, as many as 50% of male veterans and as many as 75% of female veterans report the presence of pain. In a sample of OEF and OIF veterans, approximately 47% reported at least a mild level of pain and 28% reported moderate to severe pain intensity. Chronic pain is often associated with limitation in mobility and daily activities and frequently comorbid with opioids dependency, anxiety and depression. Current available treatments medications such as NSAIDs, antiepileptic drugs, tricyclic antidepressants, corticosteroids, opioids, and cannabinoids are associated with a range of negative side effects. Invasive and surgical procedures such as peripheral nerve blockers, epidural steroid injections and neural stimulations are also used to provide effective pain relief. The long-term use of these medications often increases the potential for adverse or side effects. Thus, there is urgent needs to develop novel, efficacious and safe interventions for treating neuropathic pain. It is well established that chronic pain, such as inflammation pain, neuropathic pain, and cancer pain, is an expression of neural plasticity both in the peripheral nervous system (PNS) and in the central nervous system (CNS). A large body of evidence indicates that proinflammatory cytokines and chemokines make important contributions to the initiation and persistence of pain. Preliminary studies in our lab using a spared nerve injury (SNI) mouse model of neuropathic pain showed increased expression of CCL5 in the blood and pain phenotypes are significantly correlated with peripheral levels of CCL5. Moreover, analysis of CNS showed increased expression of CCL5 and CCR5 in the brain in the SNI mice, suggesting that CCL5/CCR5 axis may contribute to nerve injury-induced neuropathic pain. In humans, CCL5 was reported to be upregulated in patients with various pain conditions including atypical facial pain and trigeminal neuralgia, discogenic back pain and small fiber neuropathy, indicating its clinical significance in pain development. Based on these observations, we hypothesize that injury-induced increase of CCL5 and its interaction with CCR5 in the periphery and the CNS may dysregulate neural plasticity and promotes the development and persistency of pain. We propose to pharmacologically target CCL5/CCR5 using FDA approved CCR5 antagonist maraviroc in the SNI mouse mode, and use a battery of neurobehavioral tests, immunological and molecular techniques to test its efficacy and to investigate underlying mechanisms. We believe our approach will greatly enhance our understanding of the contribution of CCL5/CCR5 in chronic pain and the potential benefits of targeting CCL5/CCR5 axis as novel therapeutic intervention.

摘要/摘要 慢性疼痛是成人最常见的健康问题之一，对身体有深远影响 以及精神上的幸福。根据2020年CDC数据摘要，美国有20.4％的成年人患有慢性疼痛。 退伍军人的患病率更高。在VA医疗机构获得初级保健的退伍军人中， 多达50％的男性退伍军人和多达75％的女退伍军人报告存在疼痛。在 OEF和OIF退伍军人的样本，约有47％的人报告至少有轻度的疼痛水平，28％报告 中度至重度疼痛强度。慢性疼痛通常与流动性和日常活动的限制有关 并经常与阿片类药物依赖，焦虑和抑郁症合并。当前可用的治疗 NSAIDS，抗癫痫药，三环抗抑郁药，皮质类固醇，阿片类药物和等药物等药物 大麻素与一系列负副作用有关。侵入性和外科手术，例如 周围神经阻滞剂，硬膜外类固醇注射和神经刺激也用于提供有效 缓解疼痛。这些药物的长期使用通常会增加不良或副作用的潜力。 因此，迫切需要开发新颖，有效且安全的干预措施来治疗神经性疼痛。 众所周知，慢性疼痛，例如炎症疼痛，神经性疼痛和癌症疼痛，是一种 神经可塑性在周围神经系统（PNS）和中枢神经系统中的表达 （CNS）。大量证据表明促炎细胞因子和趋化因子使重要 疼痛的启动和持久性的贡献。使用避免神经损伤的实验室中的初步研究 （SNI）神经性疼痛的小鼠模型显示血液和疼痛中CCL5的表达增加 表型与CCL5的外围水平显着相关。此外，对中枢神经系统的分析显示 SNI小鼠中CCL5和CCR5的表达增加，表明CCL5/CCR5轴可能 导致神经损伤引起的神经性疼痛。在人类中，据报道CCL5在 患有各种疼痛条件的患者包括非典型面部疼痛和三叉神经痛，盘状背部 疼痛和小纤维神经病，表明其在疼痛发育中的临床意义。基于这些 观察结果，我们假设受伤引起的CCL5的增加及其与CCR5的相互作用 外围和中枢神经系统可能会失调神经可塑性，并促进 疼痛。我们建议使用FDA认可的CCR5拮抗剂maraviroc在药理上靶向CCL5/CCR5 SNI鼠标模式，并使用一系列神经行为测试，免疫学和分子技术 测试其功效并研究潜在的机制。 我们认为我们的方法将大大增强我们对CCL5/CCR5在 慢性疼痛和靶向CCL5/CCR5轴作为新型治疗干预的潜在益处。